British pharmaceutical firm GSK has pledged to invest $30bn (£22bn) in research and manufacturing in the US over the next ...

Drugmaker GSK said Wednesday it would invest $30 billion in U.S. research and development and supply chain infrastructure ...

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--September 15, 2025-- ...

Rising costs, policy barriers, and shrinking incentives are driving Big Pharma away from the UK, as major companies pause r&d ...

Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, ...

Rapid scientific advances are accelerating the development of medical innovations, from personalized treatments to curative ...

Medicus Pharma Ltd ( ($MDCX) ) has provided an announcement. Medicus Pharma Ltd. has completed the acquisition of Antev Limited, a UK-based ...

New draft guidelines suggest the FDA is open to exercising regulatory flexibility for non-opioid drugs being developed for chronic pain.

Recursion Pharmaceuticals (NASDAQ:RXRX) has seen significant share price volatility in 2025, dropping 27% year-to-date and trading over 55% below its 52-week high of $12. Despite this underperformance ...

A senior UK government official has questioned whether pharma companies are running a co-ordinated pressure campaign to drive up state spending on drugs, in a provocative intervention at the start of ...

The real question is how to re-shore pharmaceutical production while minimizing the costs to patients, economist Tomas J.